Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
Go back to Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS| LIGAND PHARMA (NASDAQ: LGND) | Delayed: 270.00 +7.83 (2.99%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $262.17 | 52 Week High | $139.79 | |||
| Open | $259.35 | 52 Week Low | $82.07 | |||
| Day High | $272.35 | P/E | 627.91 | |||
| Day Low | $258.00 | EPS | $0.43 | |||
| Volume | 1,106,909 | |||||
| (NASDAQ: TVTX) | Delayed: 55.42 +0.31 (0.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.11 | 52 Week High | $ | |||
| Open | $54.43 | 52 Week Low | $ | |||
| Day High | $56.00 | P/E | N/A | |||
| Day Low | $54.13 | EPS | $ | |||
| Volume | 497,201 | |||||
